Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Immuneering Corp Cl A (IMRX)

Immuneering Corp Cl A (IMRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 435,202
  • Shares Outstanding, K 64,570
  • Annual Sales, $ 0 K
  • Annual Income, $ -61,040 K
  • EBIT $ -64 M
  • EBITDA $ -64 M
  • 60-Month Beta 0.46
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.86

Options Overview Details

View History
  • Implied Volatility 273.89% (+134.95%)
  • Historical Volatility 61.04%
  • IV Percentile 93%
  • IV Rank 61.26%
  • IV High 375.12% on 11/25/25
  • IV Low 113.79% on 10/15/25
  • Expected Move (DTE 14) 1.08 (16.14%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 119
  • Volume Avg (30-Day) 361
  • Put/Call OI Ratio 0.67
  • Today's Open Interest 6,598
  • Open Int (30-Day) 6,593
  • Expected Range 5.61 to 7.77

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.31
  • Number of Estimates 3
  • High Estimate -0.27
  • Low Estimate -0.36
  • Prior Year -0.58
  • Growth Rate Est. (year over year) +46.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.98 +11.87%
on 11/07/25
7.76 -13.79%
on 11/28/25
+0.31 (+4.86%)
since 11/04/25
3-Month
5.17 +29.40%
on 09/05/25
10.08 -33.63%
on 09/22/25
+1.23 (+22.53%)
since 09/04/25
52-Week
1.10 +508.18%
on 05/12/25
10.08 -33.63%
on 09/22/25
+4.40 (+192.14%)
since 12/04/24

Most Recent Stories

More News
Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference

NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive and helping them thrive, today announced...

IMRX : 6.69 (-0.74%)
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B

EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:ALXO),(NASDAQ:ERAS),(NASDAQ:IMRX),(NASDAQ:PRLD) EQNX::TICKER_END

ONCY : 0.9807 (+8.19%)
IMRX : 6.69 (-0.74%)
ALXO : 1.3700 (+3.79%)
ERAS : 3.19 (-3.04%)
PRLD : 1.5400 (+11.59%)
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B

PALM BEACH, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The precision oncology sector is experiencing unprecedented transformation as biomarker-driven therapies and...

ONCY : 0.9807 (+8.19%)
IMRX : 6.69 (-0.74%)
ALXO : 1.3700 (+3.79%)
ERAS : 3.19 (-3.04%)
PRLD : 1.5400 (+11.59%)
Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates

- Announced extraordinary 86% overall survival at 9 months in first-line pancreatic cancer patients treated with atebimetinib + mGnP - - Raised $225 million of financing, including $25 million private...

IMRX : 6.69 (-0.74%)
Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025

- New case studies on first-line pancreatic cancer patients treated with atebimetinib in combination with FOLFIRINOX to be shared by trial investigators – - Conference call scheduled for Wednesday,...

IMRX : 6.69 (-0.74%)
Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX) and United Therapeutics (UTHR)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Immuneering (IMRX – Research Report) and United Therapeutics (UTHR – Research Report).Elevate Your Investing...

IMRX : 6.69 (-0.74%)
UTHR : 484.10 (+0.65%)
Mizuho Securities Remains a Buy on Immuneering (IMRX)

Mizuho Securities analyst Graig Suvannavejh reiterated a Buy rating on Immuneering today and set a price target of $10.00. The company’s shares closed yesterday at $6.36.Elevate Your Investing Strategy:...

IMRX : 6.69 (-0.74%)
Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it will host a conference...

IMRX : 6.69 (-0.74%)
Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi

NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the pricing of its underwritten...

IMRX : 6.69 (-0.74%)
Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced a proposed underwritten...

IMRX : 6.69 (-0.74%)

Business Summary

Immuneering Corporation is a biopharmaceutical company advancing a pipeline of oncology and neuroscience product candidates. The company's product candidate includes IMM-1-104. Immuneering Corporation is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 7.00
2nd Resistance Point 6.90
1st Resistance Point 6.80
Last Price 6.69
1st Support Level 6.59
2nd Support Level 6.49
3rd Support Level 6.39

See More

52-Week High 10.08
Last Price 6.69
Fibonacci 61.8% 6.65
Fibonacci 50% 5.59
Fibonacci 38.2% 4.53
52-Week Low 1.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar